Predictors of response to tofacitinib or etanercept in a phase 3 randomized, noninferiority study in patients with moderate to severe chronic plaque psoriasis

被引：0

作者：

Lambert, Jo ^{[1
]}

Strohal, Robert ^{[2
]}

de la Cruz, Claudia ^{[3
]}

Thaci, Diamant ^{[4
]}

Bachelez, Herve ^{[5
]}

Iversen, Lars ^{[6
]}

Rottinghaus, Scott ^{[7
]}

Tallman, Anna ^{[8
]}

Tan, Huaming ^{[7
]}

Berstein, Gabriel ^{[9
]}

机构：

[1] Ghent Univ Hosp, Ghent, Belgium

[2] Fed Acad Teaching Hosp Feldkirch, Feldkirch, Austria

[3] Clin Dermacross, Santiago, Chile

[4] Univ Med Sch, Comprehens Ctr Inflammat Med, Schleswig Holstein Campus, Lubeck, Germany

[5] Univ Paris Diderot, Sorbonne Paris Cite, Hop St Louis, AP HP, Paris, France

[6] Aarhus Univ Hosp, Aarhus C, Denmark

[7] Pfizer Inc, Groton, CT USA

[8] Pfizer Inc, New York, NY USA

[9] Pfizer Inc, Cambridge, MA USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

3386

引用

页码：AB263 / AB263

页数：1

共 50 条

[31] A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study
de Vries, A. C. Q.
Thio, H. B.
de Kort, W. J. A.
Opmeer, B. C.
van der Stok, H. M.
de Jong, E. M. G. J.
Horvath, B.
Busschbach, J. J. V.
Nijsten, T. E. C.
Spuls, Ph. I.
BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) : 624 - 633
[32] Early clinical response as a predictor of efficacy in moderate to severe psoriasis patients treated with tofacitinib in a phase 2 study
Gordon, Kenneth
Strober, Bruce
Tan, Huaming
Yang, Lingfeng
Wolk, Robert
Mallbris, Lotus
Valdez, Hernan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB231 - AB231
[33] Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials
Menter, M. Alan
Papp, Kim A.
Cather, Jennifer
Leonardi, Craig
Pariser, David M.
Krueger, James G.
Wohlrab, Johannes
Amaya-Guerra, Mario
Kaszuba, Andrzej
Nadashkevich, Oleg
Tsai, Tsen-Fang
Gupta, Pankaj
Tan, Huaming
Valdez, Hernan
Mallbris, Lotus
Tatulych, Svitlana
JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (05) : 568 - 580
[34] Efficacy and safety results of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
Menter, A.
Gottlieb, A.
Leonardi, C.
Kerdel, F.
Gu, Y.
Valdes, J.
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 : 38 - 39
[35] Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis
Leonardi, C
Goffe, B
Sobell, J
Caro, I
Wang, X
Papp, K
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A58 - A58
[36] Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis
Papp, KA
Miller, B
Gordon, KB
Caro, I
Kwon, P
Compton, PG
Leonardi, CL
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (04) : S164 - S170
[37] Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
Di Lernia, V.
Bardazzi, F.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 533 - 539
[38] Exploring the synergistic effects of cytokines as predictors of response to apremilast in patients with moderate to severe plaque psoriasis
Garcet, S.
Correa-da Rosa, J.
Nograles, K.
Schafer, P.
Krueger, J.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S42 - S42
[39] Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept
Griffiths, C. E. M.
Sterry, W.
Brock, F.
Dilleen, M.
Stefanidis, D.
Germain, J. M.
Mallbris, L.
BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (01) : 230 - 238
[40] A 12-week phase 3 study of efficacy and safety of etanercept therapy in children and adolescents with moderate to severe plaque psoriasis
Paller, Amy
Siegfried, Elaine
Langley, Richard
Gottlieb, Alice
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB195 - AB195

← 1 2 3 4 5 →